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Background: Continuous glucose monitoring (CGM) originally was developed for diabetic patients and it may be a
useful tool for monitoring glucose changes in pediatric intensive care unit (PICU). Its use is, however, limited by the
lack of sufficient data on its reliability at insufficient peripheral perfusion. We aimed to correlate the accuracy of
CGM with laboratory markers relevant to disturbed tissue perfusion.
Patients and Methods: In 38 pediatric patients (age range, 0–18 years) requiring intensive care we tested the
effect of pH, lactate, hematocrit and serum potassium on the difference between CGM and meter glucose
measurements. Guardian® (Medtronic®) CGM results were compared to GEM 3000 (Instrumentation laboratory®)
and point-of-care measurements. The clinical accuracy of CGM was evaluated by Clarke Error Grid -, Bland-Altman
analysis and Pearson’s correlation. We used Friedman test for statistical analysis (statistical significance was
established as a p < 0.05).
Results: CGM values exhibited a considerable variability without any correlation with the examined laboratory
parameters. Clarke, Bland-Altman analysis and Pearson’s correlation coefficient demonstrated a good clinical
accuracy of CGM (zone A and B = 96%; the mean difference between reference and CGM glucose was 1,3 mg/dL,
48 from the 780 calibration pairs overrunning the 2 standard deviation; Pearson’s correlation coefficient: 0.83).
Conclusions: The accuracy of CGM measurements is independent of laboratory parameters relevant to tissue
hypoperfusion. CGM may prove a reliable tool for continuous monitoring of glucose changes in PICUs, not much
influenced by tissue perfusion, but still not appropriate for being the base for clinical decisions.
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Evidence on increased overall mortality in both hypo-,
and hyperglycemia has led to an escalating interest in
glucose homeostasis disturbances in intensive care units.
Pediatric intensive care unit (PICUs) teams are commit-
ted to close monitoring of glucose, in view of the vulner-
ability of the developing central nervous system, and the
lack of appropriate clinical signs of hypoglycemia in se-
dated or unconscious patients [1-7].
Continuous glucose monitoring (CGM) originally de-
veloped for diabetic patients [8,9] may be a useful tool* Correspondence: marics.gabor@gmail.com
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unless otherwise stated.for monitoring glucose changes in pediatric or adult in-
tensive care units [10-14]. CGM could be an appropriate
additional device of PICU toolbar, but its use is limited
by the lack of convincing data on its accuracy at patho-
logical abnormalities causing tissue perfusion disturb-
ance. These clinical settings may potentially lead to
temporal shifts between glucose levels of the intravasal
and interstitial compartments. Common PICU condi-
tions characterized by diminished peripheral perfusion
are hypovolemia, shock, vasoactive therapy with dopa-
mine or noradrenaline, and hypothermia. Studies evalu-
ating the effect of the above situations on the accuracy
of CGM measurements has shown controversial results,
probable due to the heterogeneity of the critical careThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Therefore, we tested a set of laboratory parameters that
typically change in the PICU either primarily or second-
arily in parallel with glucose, measured by CGM and
meter glucose measurements to analyze whether any as-
sociations could be detected.
The following parameters were tested in our compara-
tive analysis. pH a composite marker of metabolic and/
or respiratory insufficiency; serum lactate reflecting on
tissue hypoxia; hematocrit (htc), a marker of hemocon-
centration and blood viscosity; in addition, serum potas-
sium (SeK) was included as PICU stay can often be
affected by potassium abnormalities secondary to renal
hypoperfusion and hypofiltration.
The aim of the study was to evaluate the relationship
between the accuracy of CGM, characterized by the dif-
ference of CGM and meter measurements, and blood
pH, htc, lactate and SeK values in the PICU setting.
Patients and methods
The study was approved by the local research committee
and the parents signed informed consent for each child.
Pediatric patients (between the age of 0–18 years) admit-
ted to PICU at the 1st Department of Pediatrics of Sem-
melweis University, Budapest and Bethesda Children’s
Hospital, Budapest between 1st February 2012 and 30th
June 2013, with an expected stay of at least 3 days were
enrolled. Those patients with known diabetes mellitus
were excluded from the study. CGM recordings of 40
measurements were analyzed from 38 patients.
Clinical data: mean age (range): 1.3 (0–18) years; gender:
10 females, 28 males; length of PICU stay: mean (range)
21 (1–80 days); 32/38 patients were on mechanical venti-
lation during CGM measurement; 11/38 needed vaso-
active therapy (dopamine, noradrenaline, adrenaline).
Glucose monitoring system
Interstitial glucose level was monitored by Guardian®
REAL Time (Medtronic®, USA) CGM. The flexible plat-
inum Enlite® sensor was inserted in the subcutaneous
tissue of the left or right lateral thigh and covered by
transparent dressing. Each measurement was started
after 2 hours of equilibration period. The initial calibra-
tions were performed at the beginning of the CGM
measurement and four hours afterwards. Further calibra-
tions were done regularly at least two times daily. Add-
itional calibrations were repeated as clinically needed.
The calibration was not allowed immediately after en-
teral nutrition or during rapid changes of subcutaneous
glucose (more than 1 mg/dL/min, alerted by the display).
The range of the glucose measurement by Guardian®
Real Time is 40–400 mg/dL. Reference glucose values
were obtained from blood gas analyzer (GEM 3000
Premier™, Instrumentation Laboratory®) or point-of-careglucose testing (DCONT Ideal, 77 Elektronika®). Reference
blood gas measurements were taken from arterial (77
samples), central venous (184) or capillary (276) sites.
Data analysis
For this study we used raw CGM data including the cali-
bration’s times and values, that could be exported in
comma-separated values format (.CSV) from both
Medtronic® CareLink® Professional and Medtronic® Care-
Link® Personal software. Clarke Error Grid analysis,
Bland-Altman analysis and Pearson’s correlation were
used for general characterization of the accuracy of
CGM. For this, we used both the calibrating values and
all the other documented blood gas analyzer glucose re-
sults not used for calibration. Clarke Error Grid Analysis
was developed to evaluate the accuracy of different gluc-
ometers; as its clinical and research application for deter-
mination of CGM accuracy is established. It consists of
five accuracy zones: A, B, C, D and E. Zone A represents
the glucose values that deviate by 20% or less from the ref-
erence, or are in the hypoglycemic range (<70 mg/dL)
when the reference glucose is also <70 mg/dL. In zone B
the deviation is more than 20%, however, without any clin-
ical consequence. Comparison points located in C, D or E
require special clinical attention because they could lead
to significant harm, if acted upon them The CGM clinical
accuracy is the percentage of the comparison points lo-
cated within zones A and B [17].
The effect of pH, lactate, htc, and SeK levels on the ac-
curacy of CGM were interpreted on line charts (with
standard error of mean - SEM - bars) and scatter plots.
For the line charts we stratified pH, lactate, htc, and potas-
sium levels in arbitrarily defined ranges. For each range
we calculated group’s mean for the difference between ref-
erence and CGM glucose levels. On scatter plots each
point represented the difference of a glucose pair. The
statistical effect was evaluated by repeated measures non-
parametric ANOVA (Friedman test, statistical significance
was established as a p < 0.05) with STATISTICA 8. Devel-
opment environment: MATLAB 2010b.
Results
Altogether 4199 hours of CGM recordings were analyzed
from the 40 measurements. Calibration was performed
555 times, 312 of them with archived blood gas records.
The mean time between the calibrations was 7.5 hours.
Other 225 relevant blood gas records were used for com-
parison without calibration. In total 537 blood gas records
were used for detailed analysis in the study (353 arterial/
capillary samples, and 184 venous samples).
The accuracy of the CGM was evaluated based on the
calibrating and the relevant blood gas results (n = 780).
Pearson’s correlation coefficient was 0.83. By the Clarke
Error Grid Analysis 74% of the measurement were in
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the glucose pairs fell in field C or E. The overall clinical
accuracy was 96% (zone A and zone B together). The
Bland Altman plot showed that the mean difference be-
tween reference and CGM glucose was 1,3 mg/dL, 48
calibration pairs exceeding the 2 SD (Figure 1). The
average difference of the CGM and the reference (blood
gas) glucose measurement was in the range of −2 and
8 mg/dL for all investigated parameters (Figure 2). Al-
though the mean (+SEM) lines seemed to show consid-
erable variability, in the studied range the differences
were not statistically significant. Even extreme values of
pH, lactate, htc and SeK had no effect on the accuracy
of CGM measurement. High levels of error were due to
the decreasing number of results in these ranges, but the
individual results seen on scatter plots represented a
considerably good accuracy of CGM at the extremities
(Figure 2). It was, however, notable on scatter plots that
CGM had some significant individual error in the nor-
mal ranges of investigated parameters. The pH, lactate,
htc and SeK did not influence the accuracy of CGM re-
sults even if subgroup analysis was performed for arter-
ial, venous and capillary reference measurements.
Table 1 shows the actual pH, lactate, htc, SeK and
mean glucose values associated with the ten highest glu-
cose differences compared to the reference values. Data
demonstrate that most of these values fell into or near
to the normal range. The 2 highest glucose differences
were 86 mg/dL with corresponding mean glucose values
of 353 and 207 mg/dL. Interestingly, these points were
located in the clinically acceptable Zone B of the Clarke
Error Grid Analysis (difference from the reference glu-
cose: 23 and 35%).
Discussion
Increasing efforts in order to introduce CGM into the
intensive care often face the criticism that serum andFigure 1 Left side: Clarke Error Grid analysis. The clinical accuracy of CG
Right side: Bland Altman plot, representing CGM – reference glucose differthe subcutaneous tissue are different compartments po-
tentially leading to considerable errors in glucose meas-
urement in cases of disturbed peripheral perfusion [18].
Changes of blood glucose level may appear delayed in
the interstitial space when tissue perfusion is compro-
mised. The average delay of about 10 minutes may be
significantly prolonged resulting in wide differences be-
tween the simultaneously taken blood and subcutaneous
glucose values [19]. The need for continuous glucose
measurement in the PICU could not allow an increasing
reaction time in cases of rapidly changing glucose level.
It is clinically not evident to prove or exclude the
problem of inaccurate glucose measurement in periph-
eral hypoperfusion. Many clinical scenarios could lead to
decreased tissue blood flow with other confounding
pathogenetic or therapeutic factors, making it very diffi-
cult to evaluate the effect on the accuracy of glucose
measurements. Simply, there is no homogenous patient
group in the PICU characterized by tissue hypoperfu-
sion. We aimed therefore to define a set of simply meas-
urable laboratory parameters which could characterize
tissue perfusion, and compare their effects on the accur-
acy of glucose measurements in the subcutaneous space.
Metabolic acidosis primarily due to anaerobic lactate
production is evidently one of the most frequently rec-
ognized markers of tissue hypoperfusion. Therefore
pH and serum lactate were chosen as key elements of
our laboratory tools. In many cases, especially in
pediatrics, hypovolemia and secondary hemoconcentra-
tion play significant role in disturbed microcirculation.
Hematocrit was chosen as an element of our tools based
on this approach. Finally, renal function is commonly
altered by systemic hypoperfusion, easily detectable
from clinical signs such as oligo-anuria, leading to sig-
nificant morbidity. From practical aspects we have
chosen serum potassium as a secondary marker of pos-
sibly decreased renal perfusion.M was 96% as a result of 780 CGM – reference glucose pair analysis.
ences in function of mean glucose values.
Figure 2 (See legend on next page.)
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Figure 2 Left side: Line charts with error bars (standard error of mean [SEM]). The data points represent the mean difference between the
blood gas and CGM glucose concentrations in function of pH, lactate, htc and SeK levels. Right side: Scatter plots. Every rectangle represents the
difference between the blood gas and CGM glucose concentrations in function of pH, lactate, htc and SeK levels. In three cases the difference
between blood gas and CGM glucose exceeded 80 mg/dL.
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by many other conditions as well. An important consider-
ation for our study was the possibility of measuring these
values by a simple bed-side method parallel with blood
glucose measurements necessary for CGM calibration.
The GEM 3000 blood gas analyzer provides reliable cali-
brated measurements of all the four above parameters
along with blood glucose from venous, capillary or arterial
samples, measurements being routinely performed in
PICU settings.
With this unique novel approach we could compare
537 pairs of blood and interstitial glucose measurements
in an unselected PICU population in function of pH, lac-
tate, htc and Se K. Obviously, a small number of measure-
ments fell in the extreme ranges. The average difference of
glucose concentrations was in a considerably narrow
range, even at the extremities around 8 mg/dL. pH values
< 7.2 and SeK < 3 mmol/L appear to have some effect on
the accuracy of CGM measurements, without statistical
significance. This could be due to the low number of
paired values at these ranges, the scatter plots of all the
measurements, however, do not confirm higher dispersion
of glucose differences in acidosis, hypokalemia or hyper-
lactatemia. On the contrary, CGM and reference deviation
seems to be relatively low at these states. Three previous
studies could not prove the negative effect of vasopressors
[16], hypothermia [16] or septic shock [14,15] on the ac-
curacy of CGM, which results are in accordance with our
findings.Table 1 The ten highest glucose differences
Blood gas analysis (n = 537)
No. Ref-CGM pH Lactate Htc Se K Mean M
1 86 7,41 0,3 36 4,3 353
2 86 7,34 3,4 39 5,1 207
3 81 7,21 0,4 30 3,8 132
4 72 7,54 1,3 26 3,6 86
5 67 7,36 0,6 31 4,4 96
6 65 7,2 0,3 34 3,8 135
7 65 7,28 0,5 36 4,5 145
8 −65 7,42 2,4 38 3,5 95
9 61 7,33 0,5 35 4,4 72
10 61 7,41 0,6 28 5,1 96
Ref-CGM = reference-CGM glucose (mg/dL); Htc – Hematoctit (%).
Lactate (mmol/L); SeK – serum potassium (mmol/L).
Mean M - Mean of the two measurements (mg/dL).Some data indicate that there is a lack of agreement
between arterial and venous blood glucose measure-
ments in PICU setting [20], suggesting that sampling site
could play a significant role in CGM calibration and in-
sulin therapy. To address this issue we performed a se-
lective analysis of our data pairs from arterial, venous
and capillary blood samples. We could not demonstrate
any difference in CGM accuracy between these groups,
but the limited number of cases in arterial and venous
groups does not allow us to conclude about the equiva-
lence of the samples.
Scatter plots show a remarkably high variability of glu-
cose differences at the normal range of all four examined
parameters reaching 80 mg/dL in three cases. This ob-
servation points out to the known limitations of CGM.
Based on our results the measurement error showed sto-
chastic distribution rather than exact mathematical nexus,
i.e. more measurements - more errors. The question arises
which factors are responsible for the inaccuracy of the
CGM in PICU settings. A recent study demonstrated that
more frequent calibrations (6 hourly) may improve the
precision [21]. Other possible, but so far not examined
factor is the displacement of the platinum electrode due
to the rotation of the PICU patients, being a common
anti-decubitus therapy in pediatrics. Furthermore, the
Guardian®’s wireless communication might be disturbed
by electric interference of the PICU’s electric devices.
Very recently, a new generation of CGM monitor was
developed (Medtronic Sentrino®), especially for critical
care units, with higher accuracy of glucose measure-
ments [22].
Based on the Clarke Error Grid Analysis of our mea-
surements we could state that the clinical accuracy of
CGM in our study corresponds to those results in the
literature, being in the acceptable range. It remains,
however, a right question if conventional CGM is ready
for use as a therapeutic guide in the ICU with these limi-
tations of accuracy. It is important to emphasize that
CGM is a perfect tool for indicating changes of glucose
level in the ICU with a need for confirmation with other
methods of blood glucose determination.
Conclusions
Our results confirm that CGM is a valuable tool in the
continuous measurement of glucose levels in the sub-
cutaneous tissue with restrictive inaccuracy for the PICU
use. CGM data are very useful for trend analysis in
PICU, but the therapy should not be based on CGM
Marics et al. Italian Journal of Pediatrics  (2015) 41:17 Page 6 of 6values without a confirming reference measurement. The
accuracy of CGM is not dependent on the changes of la-
boratory parameters indicative for tissue hypoperfusion,
thus those states typical for PICU patients with disturbed
microcirculation do not further limit its suitability.
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